Mitchell L. Doucette, PhD, MS

Mitchell L. Doucette, PhD, MS, is a nationally recognized epidemiologist and research leader whose work sits at the intersection of Epidemiology, Health Economics and Outcomes Research (HEOR), and real-world evidence. With over a decade of experience spanning academia and the pharmaceutical industry, Dr. Doucette applies advanced causal inference methodologies to inform clinical, regulatory, and commercial decision-making.

Dr. Doucette currently serves as a Senior Advisor, Health Economics and Outcomes Research (HEOR) Scientist at Eli Lilly and Company, where he leads the development and application of real-world evidence strategies to support value demonstration, payer engagement, and clinical decision-making. In this role, he designs and executes observational and economic studies, including cost-effectiveness and outcomes research, and partners cross-functionally with clinical, access, and commercial teams to translate evidence into actionable insights. His work focuses on integrating patient-reported outcomes, real-world data, and advanced analytic methods to inform product strategy and healthcare decision-making in a rapidly evolving evidence landscape.

Prior to joining Lilly, Dr. Doucette served as Senior Director of Health Economics and Outcomes Research at Leafwell, a healthcare technology company. In this role, he led the design and execution of observational research using patient-reported and administrative data to evaluate treatment outcomes, safety, and healthcare utilization. He collaborated across product, clinical, and commercial teams to generate evidence supporting market positioning and access strategies, while building scalable research infrastructure and contributing to the company’s broader evidence generation strategy.

Before transitioning to industry, Dr. Doucette served as Director of Research Methods and Assistant Scientist at the Johns Hopkins Bloomberg School of Public Health, where he developed award-winning methodologies to evaluate the impact of health interventions and public policy. His novel statistical estimator, published in the American Journal of Epidemiology, has been cited by leading academics and policymakers, including in a U.S. Supreme Court decision.

Dr. Doucette is a two-time recipient of “Best Paper of the Year” awards, has secured over $6.5 million in competitive research funding, and has authored more than 35 peer-reviewed publications. He is known for translating complex research into actionable insights, advising both C-suite executives and academic collaborators on evidence generation that drives strategic outcomes.

He received his PhD from the Johns Hopkins Bloomberg School of Public Health in 2018 with a focus on Health Policy and Management. He received his MS and BS from the University of Massachusetts Amherst.